Benzinga | Jan 11, 2022 04:31PM EST

Integra LifeSciences Says Planning $125M Buyback As Part Of Previous Approval For Up To $225M Repurchase Authorization

* Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year.

* Full-year 2021 revenue is expected to be in a range of $1,541 million to $1,543 million, representing an increase of approximately 12% on a reported basis and an increase of approximately 14% on an organic basis compared to the prior year.

* The company is planning a $125 million share repurchase as a part of a previous approval by the Board of Directors, with an authorization of up to $225 million.